PRINCETON, N.J.--(BUSINESS WIRE)--PhytoMedical Technologies, Inc. (OTCBB: PYTO) (FWB: ET6), today announced that its patented bis-intercalator anti-cancer compound achieved a 50% or greater cancer cell kill rate in new in vitro studies of the DMS 114 strain of human small lung cancer cells, an important outcome given lung cancer’s high mortality rate and the lack of effective treatment options.
